In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis

被引：40
作者：
Chen, YH
Garber, E
Zhao, QQ
Ge, YG
Wikler, MA
Kaniga, K
Saiman, L
机构：
[1] Columbia Univ, Dept Pediat, New York, NY 10032 USA
[2] Peninsula Pharmaceut Inc, Alameda, CA USA
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2005年 / 49卷 / 06期
关键词：
D O I：
10.1128/AAC.49.6.2510-2511.2005
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Doripenem 50% inhibitory concentrations (MIC50) and 90% inhibitory concentrations (MIC90) for multidrug-resistant strains of mucoid Pseudomonas aeruginosa (n = 200 strains), nonmucoid P. aeruginosa (n = 200), and Burkholdetia cepacia complex (n = 200) isolated from patients with cystic fibrosis were 8 and 32, 8 and 64, and 8 and 32 mu g/ml, respectively. Doripenem had somewhat better activity than established antimicrobial agents.
引用
收藏
页码：2510 / 2511
页数：2
相关论文
共 11 条
[1]  
BLUMER J, IN PRESS CHEST
[2]   In vitro antimicrobial activity of doripenem, a new carbapenem [J].
Ge, YG ;
Wikler, MA ;
Sahm, DF ;
Blosser-Middleton, RS ;
Karlowsky, JA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (04) :1384-1396
[3]   MICROBIOLOGY OF AIRWAY DISEASE IN PATIENTS WITH CYSTIC-FIBROSIS [J].
GILLIGAN, PH .
CLINICAL MICROBIOLOGY REVIEWS, 1991, 4 (01) :35-51
[4]  
LiPuma J J, 1998, Curr Opin Pulm Med, V4, P337, DOI 10.1097/00063198-199811000-00005
[5]   Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized β-lactamases [J].
Mushtaq, S ;
Ge, YG ;
Livermore, DM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (04) :1313-1319
[6]  
*NAT COMM CLIN LAB, 2002, M100S12 NCCLS, P43
[7]  
*NAT COMM CLIN LAB, 2004, M100S14 NCCLS, V24, P36
[8]   Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation [J].
Saiman, L ;
Mehar, F ;
Niu, WW ;
Neu, HC ;
Shaw, KJ ;
Miller, G ;
Prince, A .
CLINICAL INFECTIOUS DISEASES, 1996, 23 (03) :532-537
[9]   Infection control recommendations for patients with cystic fibrosis: Microbiology, important pathogens, and infection control practices to prevent patient-to-patient-transmission [J].
Saiman, L ;
Siegel, J .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2003, 24 (05) :S6-S52
[10]   In vitro and in vivo antibacterial activities of S-4661, a new carbapenem [J].
Tsuji, M ;
Ishii, Y ;
Ohno, A ;
Miyazaki, S ;
Yamaguchi, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (01) :94-99
12